Anti-PD-1 promising for first-line melanoma therapy

A leading international oncologist at the MOGA Annual Scientific Meeting says he “strongly considers” the anti-PD-1 drug pembrolizumab as first-line treatment for melanoma.

Oncologist Dr Adil Daud, lead investigator for the KEYNOTE001 clinical trials of pembrolizumab at the University of California San Francisco, presented the trial results at the conference (August 5-7).